GENEVA, December 16 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with US ranked Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.
"We are extremely proud to announce this valuablecollaboration with the renowned Brigham and Women's Hospital," says Dr.
The collaboration will focus on three key areas, each with thegoal of identifying new and better ways to manage neurodegenerativeconditions including MS:
Additional projects may be added to the scope of thecollaboration on an ongoing basis.
This unique collaboration will create an unprecedentedcombination of expertise between Merck Serono, a leader in thebiopharmaceutical industry with marketed products to treat MS, as well asBrigham and Women's, a globally recognized hospital, academic, and researchinstitution.
"The strategic alliance with Merck Serono allows us tocollaborate with a leading biopharmaceutical organization to strengthen ourunderstanding of the disease pathology behind neurological diseases like MS,"said Dr.
This agreement underscores Merck Serono's commitment topartnering with leading academic and medical institutions in an effort todrive forward late-stage research and early-stage clinical development in MSand other neurodegenerative diseases.
About Merck Serono
Merck Serono is the division for innovative prescriptionpharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceuticaland chemical company. Headquartered in Geneva, Switzerland, Merck Seronodiscovers, develops, manufactures and markets innovative small molecules andbiopharmaceuticals to help patients with unmet medical needs. In the UnitedStates and Canada, EMD Serono operates through separately incorporatedaffiliates.
Merck Serono has leading brands serving patients with cancer (Erbitux(R),cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility(Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R)and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as wellas cardiometabolic diseases (Glucophage(R), metformin), (Concor(R),bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available inall markets.
With an annual R&D expenditure of around EUR 1bn, Merck Seronois committed to growing its business in specialist-focused therapeutic areasincluding neurodegenerative diseases, oncology, fertility and endocrinology,as well as new areas potentially arising out of research and development inautoimmune and inflammatory diseases.
Merck is a global pharmaceutical and chemical company withtotal revenues of EUR 7.6 billion in 2008, a history that began in 1668, anda future shaped by approximately 33,000 employees in 60 countries. Itssuccess is characterized by innovations from entrepreneurial employees.Merck's operating activities come under the umbrella of Merck KGaA, in whichthe Merck family holds an approximately 70% interest and free shareholdersown the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co.was expropriated and has been an independent company ever since.
Last updated on: 27/08/2010
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.